皮肤型红斑狼疮和皮肌炎中抗疟药引起的药物性皮肤不良反应：一项回顾性队列研究。 - Suppr

Suppr

超能文献

Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.

作者信息

Gonzalez Cristian D, Hansen Christopher, Clarke Jennie T

机构信息

Department of Dermatology, University of Utah, Salt Lake City, Utah.

出版信息

J Am Acad Dermatol. 2019 Sep;81(3):859-860. doi: 10.1016/j.jaad.2019.04.068. Epub 2019 May 11.

DOI:10.1016/j.jaad.2019.04.068

PMID:31085265

Abstract

摘要

相似文献

Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.皮肤型红斑狼疮和皮肌炎中抗疟药引起的药物性皮肤不良反应：一项回顾性队列研究。

J Am Acad Dermatol. 2019 Sep;81(3):859-860. doi: 10.1016/j.jaad.2019.04.068. Epub 2019 May 11.

Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.皮肤型红斑狼疮和皮肌炎患者的抗疟药毒性：一项回顾性队列研究。

J Am Acad Dermatol. 2018 Jan;78(1):100-106.e1. doi: 10.1016/j.jaad.2017.09.061. Epub 2017 Oct 6.

Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.与皮肤型红斑狼疮患者相比，羟氯喹引起的不良皮肤反应在皮肌炎患者中更为常见。

Arch Dermatol. 2002 Sep;138(9):1231-3; discussion 1233. doi: 10.1001/archderm.138.9.1231.

Therapeutic efficacy and adverse events of hydroxychloroquine administration in Japanese systemic/cutaneous lupus erythematosus patients.羟氯喹给药对日本系统性/皮肤型红斑狼疮患者的治疗效果及不良事件

J Dermatol. 2018 Aug;45(8):1020-1022. doi: 10.1111/1346-8138.14512.

The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.在一群皮肤红斑狼疮和皮肌炎患者中使用阿的平的经验。

J Am Acad Dermatol. 2017 Aug;77(2):374-377. doi: 10.1016/j.jaad.2017.03.027.

Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.在患有红斑狼疮的患者中，因无效或不耐受而更换抗疟药物：一项多中心观察性研究。

J Am Acad Dermatol. 2018 Jan;78(1):107-114.e1. doi: 10.1016/j.jaad.2017.08.045. Epub 2017 Oct 20.

Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.米帕林与羟氯喹联合治疗系统性红斑狼疮伴难治性皮肤和关节活动患者。

Lupus. 2018 Sep;27(10):1718-1722. doi: 10.1177/0961203318768877. Epub 2018 Apr 10.

[Synthetic antimalarials and skin].[合成抗疟药与皮肤]

Ann Dermatol Venereol. 1990;117(12):975-90.

The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.增加羟氯喹（HCQ）剂量对难治性皮肤红斑狼疮（CLE）患者的影响：一项开放标签前瞻性初步研究。

J Am Acad Dermatol. 2016 Apr;74(4):693-9.e3. doi: 10.1016/j.jaad.2015.09.064. Epub 2016 Feb 3.

Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.皮肌炎、红斑狼疮和扁平苔藓性毛发角化病患者中继发于羟氯喹的皮肤不良反应。

J Am Acad Dermatol. 2021 Oct;85(4):1046-1047. doi: 10.1016/j.jaad.2021.02.034. Epub 2021 Feb 17.

引用本文的文献

Higher Odds of Adverse Cutaneous Reactions in Patients With Dermatomyositis Treated With Hydroxychloroquine Compared With Methotrexate.与甲氨蝶呤相比，皮肌炎患者使用羟氯喹治疗出现皮肤不良反应的几率更高。

ACR Open Rheumatol. 2023 Nov;5(11):594-599. doi: 10.1002/acr2.11605. Epub 2023 Sep 24.

Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.新型冠状病毒肺炎患者与非新型冠状病毒肺炎患者短期口服氯喹和羟氯喹治疗的安全性：一项系统评价

Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634.

Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.羟氯喹在 COVID-19 和其他疾病中的安全性：53 项随机试验的系统评价和荟萃分析。

Eur J Clin Pharmacol. 2021 Jan;77(1):13-24. doi: 10.1007/s00228-020-02962-5. Epub 2020 Aug 11.

COVID-19 and dermatology.新型冠状病毒肺炎与皮肤病学。

Turk J Med Sci. 2020 Dec 17;50(8):1751-1759. doi: 10.3906/sag-2005-182.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验